Wockhardt Ltd

Net Loss of Wockhardt reported to Rs 25.00 crore in the quarter ended March 2025 as against net loss of Rs 169.00 crore during the previous quarter ended March 2024. Sales rose 6.14% to Rs 743.00 crore in the quarter ended March 2025 as against Rs 700.00 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 47.00 crore in the year ended March 2025 as against net loss of Rs 463.00 crore during the previous year ended March 2024. Sales rose 7.65% to Rs 3012.00 crore in the year ended March 2025 as against Rs 2798.00 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales743.00700.00 6 3012.002798.00 8 OPM %8.61-8.43 -13.053.25 - PBDT31.00-78.00 LP 201.00-131.00 LP PBT-22.00-136.00 84 -16.00-354.00 95 NP-25.00-169.00 85 -47.00-463.00 90 Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live

Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland). Consequent to the incorporation, Wockhardt Antibiotics (Ireland) has become a Step-Down Subsidiary of the Company. Powered by Capital Market - Live

The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a life-threatening blood and liver infection resistant to nine different antibiotics over 45 days. The infection, caused by NDM-producing E. coli, persisted despite treatment with multiple last-resort antibiotics, including Tigecycline, Polymyxin B, and Ceftazidime/avibactam + Aztreonam. With limited treatment options left, doctors at St. Jude's Hospital, Memphis, USA, sought compassionate use approval from the US FDA to administer Zaynich. Over 41 days of treatment, the patient made a full recovery, marking the third successful US case treated with Wockhardt's novel β-lactam enhancer antibiotic. Zaynich, a proprietary β-lactam enhancer antibiotic, has now been used under compassionate use in 51 critically ill patients globally, demonstrating its potential against multi-drug resistant Gram-negative infections. The drug recently completed Phase III global trials, paving the way for marketing approvals worldwide. Wockhardt is a research based global pharmaceutical and biotech company. The company reported consolidated net profit of Rs 14 crore in Q3 FY25 as against net loss of Rs 83 crore in Q3 FY24. Net sales rose 2.9% year on year to Rs 721 crore in Q3 FY25. Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live

Miqnaf is an ultra-short course, once-a-day, 3-day treatment for CABP, including those caused by multi-drug-resistant (MDR) pathogens. The approval follows a favourable recommendation for manufacture and marketing of nafithromycin from the Subject Expert Committee (SEC) of CDSCO. Over 15 years, Miqnaf underwent extensive non-clinical and clinical studies, including human trials in the US, Europe, South Africa, and India. It represents a new macrolide-based treatment for CABP in India after a gap of nearly 30 years. Moreover, the ultra-short course regimen is said to enhance patients' compliance with treatment, resulting in favourable outcomes. In India, antibiotic resistance is a burning issue, including in community pneumonia cases. A key strength of Miqnaf is its ability to target a wide range of respiratory infections, including bacteria resistant to common antibiotics like azithromycin and amoxicillin/clavulanate, making it a strong single-treatment option for pneumonia. CABP affects millions of people worldwide, with 23% of the global disease burden borne by India. Several bacterial pathogens could cause CABP and other respiratory infections, the dominant being S. pneumoniae and H. influenzae and atypical respiratory pathogens such as Mycoplasma, Chlamydia, and Legionella. Mumbai-based Wockhardt is a research-based global pharmaceutical and biotech company. Employing around ~2600 people and 27 nationalities, it has a presence in the USA, UK, Ireland, Switzerland, France, Mexico, Russia, and many other countries. It has manufacturing and research facilities in India and the UK and a manufacturing facility in Ireland. Around 78% of its global revenues are coming from international businesses. The company reported consolidated net loss of Rs 16 crore in Q2 FY25 as against net loss of Rs 35 crore posted in Q2 FY24. Net sales rose 7.43% year on year to Rs 809 crore in Q2 FY25.Powered by Capital Market - Live

Net Loss of Wockhardt reported to Rs 22.00 crore in the quarter ended September 2024 as against net loss of Rs 77.00 crore during the previous quarter ended September 2023. Sales rose 7.44% to Rs 809.00 crore in the quarter ended September 2024 as against Rs 753.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales809.00753.00 7 OPM %13.609.56 - PBDT46.0020.00 130 PBT-9.00-35.00 74 NP-22.00-77.00 71 Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

The floor price indicates a steep discount of 8.5% over the stock's closing price on Wednesday. The media reported that the QIP is aimed to raise up to Rs 1,000 crore, with an additional greenshoe option of Rs 200 crore. A QIP is a method by which a company raises funds by allotting shares to eligible institutional buyers. According to reports, the QIP is expected to dilute Wockhardt's equity by around 5.57% of its post-issue capital. Based on the September shareholding pattern, promoters of Wockhardt held a 51.99% stake in the company. Mumbai-based Wockhardt is a research based global pharmaceutical and biotech company. Employing around ~2600 people and 27 nationalities, it has a presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland. Around 78% of its global revenues is coming from international businesses. Powered by Capital Market - Live

Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ongoing commitment to address the growing diabetes epidemic both in India and globally. Wockhardt's Aspart insulin injection (ASPARAPID) is an indigenously developed product, underscoring the company's end-to-end capabilities in research development - from research to production through in-house development. It offers enhanced quality and accessibility for patients. ASPARAPID will be available in cartridges, vials, and prefilled disposable pens, offering flexibility to the patients for management of diabetes. The market size of Aspart in India is currently estimated over Rs 260 crore with only 2 players and is expected to grow significantly in the coming years. 'We are proud of adding another feather in our diabetes biosimilars portfolio through filing of insulin Aspart injection in a market that has limited competition. This reinforces Wockhardt's ability to develop and manufacture complex biosimilars domestically,' said Dr. Habil Khorakiwala, Founder Chairman of Wockhardt. 'Our aim is to make world-class diabetes care accessible to patients in India and globally and to contribute meaningfully to the management of diabetes.' Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions. The introduction of these products will further strengthen Wockhardt's diabetes portfolio, offering patients more effective treatment options for managing their condition. Powered by Capital Market - Live